nodes	percent_of_prediction	percent_of_DWPC	metapath
Paliperidone—Iloperidone—Gefitinib—lung cancer	0.576	1	CrCrCtD
Paliperidone—CYP3A5—Gefitinib—lung cancer	0.0211	0.1	CbGbCtD
Paliperidone—CYP3A5—Teniposide—lung cancer	0.0205	0.0971	CbGbCtD
Paliperidone—CYP2D6—Gefitinib—lung cancer	0.0129	0.0614	CbGbCtD
Paliperidone—CYP3A5—Crizotinib—lung cancer	0.0129	0.0614	CbGbCtD
Paliperidone—CYP3A5—Erlotinib—lung cancer	0.0125	0.0592	CbGbCtD
Paliperidone—CYP3A5—Paclitaxel—lung cancer	0.0114	0.0542	CbGbCtD
Paliperidone—CYP3A5—Irinotecan—lung cancer	0.0113	0.0535	CbGbCtD
Paliperidone—CYP2D6—Vinorelbine—lung cancer	0.00997	0.0473	CbGbCtD
Paliperidone—CYP3A5—Etoposide—lung cancer	0.00902	0.0428	CbGbCtD
Paliperidone—CYP3A4—Topotecan—lung cancer	0.00899	0.0427	CbGbCtD
Paliperidone—CYP3A5—Docetaxel—lung cancer	0.00826	0.0392	CbGbCtD
Paliperidone—CYP3A4—Gefitinib—lung cancer	0.00823	0.039	CbGbCtD
Paliperidone—CYP3A4—Teniposide—lung cancer	0.00798	0.0379	CbGbCtD
Paliperidone—CYP2D6—Erlotinib—lung cancer	0.00765	0.0363	CbGbCtD
Paliperidone—CYP3A4—Vinorelbine—lung cancer	0.00634	0.0301	CbGbCtD
Paliperidone—CYP2D6—Vinblastine—lung cancer	0.00614	0.0291	CbGbCtD
Paliperidone—CYP3A4—Crizotinib—lung cancer	0.00504	0.0239	CbGbCtD
Paliperidone—CYP3A4—Erlotinib—lung cancer	0.00486	0.0231	CbGbCtD
Paliperidone—CYP3A4—Paclitaxel—lung cancer	0.00445	0.0211	CbGbCtD
Paliperidone—CYP3A4—Irinotecan—lung cancer	0.00439	0.0208	CbGbCtD
Paliperidone—CYP3A4—Vinblastine—lung cancer	0.00391	0.0185	CbGbCtD
Paliperidone—CYP2D6—Doxorubicin—lung cancer	0.00377	0.0179	CbGbCtD
Paliperidone—CYP3A4—Etoposide—lung cancer	0.00352	0.0167	CbGbCtD
Paliperidone—CYP3A4—Docetaxel—lung cancer	0.00322	0.0153	CbGbCtD
Paliperidone—CYP3A4—Doxorubicin—lung cancer	0.0024	0.0114	CbGbCtD
Paliperidone—HTR2A—phrenic nerve—lung cancer	0.00196	0.377	CbGeAlD
Paliperidone—HTR2A—pulmonary artery—lung cancer	0.000711	0.137	CbGeAlD
Paliperidone—Iloperidone—CYP2E1—lung cancer	0.000415	0.641	CrCbGaD
Paliperidone—Risperidone—ABCB1—lung cancer	0.000232	0.358	CrCbGaD
Paliperidone—DRD2—respiratory system—lung cancer	0.000181	0.0349	CbGeAlD
Paliperidone—ADRA1A—epithelium—lung cancer	0.000155	0.0298	CbGeAlD
Paliperidone—CYP3A5—respiratory system—lung cancer	0.000148	0.0284	CbGeAlD
Paliperidone—ADRA2C—bronchus—lung cancer	0.000145	0.0279	CbGeAlD
Paliperidone—HRH1—respiratory system—lung cancer	0.000143	0.0276	CbGeAlD
Paliperidone—ADRA2C—trachea—lung cancer	0.00013	0.0251	CbGeAlD
Paliperidone—ADRA2C—cardiac atrium—lung cancer	0.000122	0.0236	CbGeAlD
Paliperidone—HRH1—epithelium—lung cancer	0.00012	0.023	CbGeAlD
Paliperidone—HTR2A—respiratory system—lung cancer	0.00012	0.023	CbGeAlD
Paliperidone—ADRA2A—bronchus—lung cancer	0.000116	0.0223	CbGeAlD
Paliperidone—HRH1—trachea—lung cancer	0.000106	0.0204	CbGeAlD
Paliperidone—ADRA2A—trachea—lung cancer	0.000104	0.02	CbGeAlD
Paliperidone—HTR2A—epithelium—lung cancer	0.0001	0.0192	CbGeAlD
Paliperidone—ADRA2A—cardiac atrium—lung cancer	9.77e-05	0.0188	CbGeAlD
Paliperidone—DRD2—lung—lung cancer	9.63e-05	0.0185	CbGeAlD
Paliperidone—ADRA2C—lung—lung cancer	9.36e-05	0.018	CbGeAlD
Paliperidone—HTR2A—trachea—lung cancer	8.84e-05	0.017	CbGeAlD
Paliperidone—CYP3A5—lung—lung cancer	7.84e-05	0.0151	CbGeAlD
Paliperidone—HRH1—lung—lung cancer	7.61e-05	0.0146	CbGeAlD
Paliperidone—ADRA2A—lung—lung cancer	7.47e-05	0.0144	CbGeAlD
Paliperidone—ADRA2C—lymph node—lung cancer	6.4e-05	0.0123	CbGeAlD
Paliperidone—HTR2A—lung—lung cancer	6.35e-05	0.0122	CbGeAlD
Paliperidone—HRH1—lymph node—lung cancer	5.2e-05	0.01	CbGeAlD
Paliperidone—ADRA2A—lymph node—lung cancer	5.11e-05	0.00983	CbGeAlD
Paliperidone—Upper respiratory tract infection—Doxorubicin—lung cancer	4.25e-05	0.00029	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Paclitaxel—lung cancer	4.24e-05	0.00029	CcSEcCtD
Paliperidone—Fatigue—Paclitaxel—lung cancer	4.24e-05	0.000289	CcSEcCtD
Paliperidone—Pollakiuria—Doxorubicin—lung cancer	4.22e-05	0.000289	CcSEcCtD
Paliperidone—Asthenia—Gemcitabine—lung cancer	4.21e-05	0.000288	CcSEcCtD
Paliperidone—Pain—Paclitaxel—lung cancer	4.2e-05	0.000287	CcSEcCtD
Paliperidone—Constipation—Paclitaxel—lung cancer	4.2e-05	0.000287	CcSEcCtD
Paliperidone—Confusional state—Docetaxel—lung cancer	4.2e-05	0.000287	CcSEcCtD
Paliperidone—Urinary tract disorder—Methotrexate—lung cancer	4.17e-05	0.000285	CcSEcCtD
Paliperidone—Anaphylactic shock—Docetaxel—lung cancer	4.17e-05	0.000285	CcSEcCtD
Paliperidone—Oedema—Docetaxel—lung cancer	4.17e-05	0.000285	CcSEcCtD
Paliperidone—Weight increased—Doxorubicin—lung cancer	4.16e-05	0.000284	CcSEcCtD
Paliperidone—Pruritus—Gemcitabine—lung cancer	4.15e-05	0.000284	CcSEcCtD
Paliperidone—Urethral disorder—Methotrexate—lung cancer	4.14e-05	0.000283	CcSEcCtD
Paliperidone—Infection—Docetaxel—lung cancer	4.14e-05	0.000283	CcSEcCtD
Paliperidone—Weight decreased—Doxorubicin—lung cancer	4.14e-05	0.000283	CcSEcCtD
Paliperidone—Feeling abnormal—Etoposide—lung cancer	4.13e-05	0.000282	CcSEcCtD
Paliperidone—Hyperglycaemia—Doxorubicin—lung cancer	4.12e-05	0.000282	CcSEcCtD
Paliperidone—Diarrhoea—Irinotecan—lung cancer	4.12e-05	0.000282	CcSEcCtD
Paliperidone—Pneumonia—Doxorubicin—lung cancer	4.1e-05	0.00028	CcSEcCtD
Paliperidone—Gastrointestinal pain—Etoposide—lung cancer	4.1e-05	0.00028	CcSEcCtD
Paliperidone—Shock—Docetaxel—lung cancer	4.1e-05	0.00028	CcSEcCtD
Paliperidone—Nervous system disorder—Docetaxel—lung cancer	4.09e-05	0.000279	CcSEcCtD
Paliperidone—Thrombocytopenia—Docetaxel—lung cancer	4.08e-05	0.000279	CcSEcCtD
Paliperidone—Infestation NOS—Doxorubicin—lung cancer	4.08e-05	0.000278	CcSEcCtD
Paliperidone—Infestation—Doxorubicin—lung cancer	4.08e-05	0.000278	CcSEcCtD
Paliperidone—Tachycardia—Docetaxel—lung cancer	4.07e-05	0.000278	CcSEcCtD
Paliperidone—Feeling abnormal—Paclitaxel—lung cancer	4.05e-05	0.000277	CcSEcCtD
Paliperidone—Skin disorder—Docetaxel—lung cancer	4.05e-05	0.000276	CcSEcCtD
Paliperidone—Hypersensitivity—Cisplatin—lung cancer	4.03e-05	0.000275	CcSEcCtD
Paliperidone—Gastrointestinal pain—Paclitaxel—lung cancer	4.02e-05	0.000275	CcSEcCtD
Paliperidone—Diarrhoea—Gemcitabine—lung cancer	4.02e-05	0.000274	CcSEcCtD
Paliperidone—Dizziness—Irinotecan—lung cancer	3.99e-05	0.000272	CcSEcCtD
Paliperidone—Urticaria—Etoposide—lung cancer	3.98e-05	0.000272	CcSEcCtD
Paliperidone—Jaundice—Doxorubicin—lung cancer	3.97e-05	0.000271	CcSEcCtD
Paliperidone—Anorexia—Docetaxel—lung cancer	3.97e-05	0.000271	CcSEcCtD
Paliperidone—Abdominal pain—Etoposide—lung cancer	3.96e-05	0.000271	CcSEcCtD
Paliperidone—Body temperature increased—Etoposide—lung cancer	3.96e-05	0.000271	CcSEcCtD
Paliperidone—Conjunctivitis—Doxorubicin—lung cancer	3.96e-05	0.000271	CcSEcCtD
Paliperidone—Urinary tract infection—Doxorubicin—lung cancer	3.96e-05	0.000271	CcSEcCtD
Paliperidone—Eye disorder—Methotrexate—lung cancer	3.95e-05	0.00027	CcSEcCtD
Paliperidone—Tinnitus—Methotrexate—lung cancer	3.94e-05	0.000269	CcSEcCtD
Paliperidone—Asthenia—Cisplatin—lung cancer	3.93e-05	0.000268	CcSEcCtD
Paliperidone—Cardiac disorder—Methotrexate—lung cancer	3.92e-05	0.000268	CcSEcCtD
Paliperidone—Urticaria—Paclitaxel—lung cancer	3.9e-05	0.000267	CcSEcCtD
Paliperidone—Hypotension—Docetaxel—lung cancer	3.89e-05	0.000266	CcSEcCtD
Paliperidone—Body temperature increased—Paclitaxel—lung cancer	3.89e-05	0.000265	CcSEcCtD
Paliperidone—Abdominal pain—Paclitaxel—lung cancer	3.89e-05	0.000265	CcSEcCtD
Paliperidone—Hepatobiliary disease—Doxorubicin—lung cancer	3.86e-05	0.000263	CcSEcCtD
Paliperidone—Epistaxis—Doxorubicin—lung cancer	3.85e-05	0.000263	CcSEcCtD
Paliperidone—Angiopathy—Methotrexate—lung cancer	3.83e-05	0.000262	CcSEcCtD
Paliperidone—Vomiting—Irinotecan—lung cancer	3.83e-05	0.000262	CcSEcCtD
Paliperidone—Sinusitis—Doxorubicin—lung cancer	3.82e-05	0.000261	CcSEcCtD
Paliperidone—Immune system disorder—Methotrexate—lung cancer	3.82e-05	0.000261	CcSEcCtD
Paliperidone—Mediastinal disorder—Methotrexate—lung cancer	3.81e-05	0.00026	CcSEcCtD
Paliperidone—Agranulocytosis—Doxorubicin—lung cancer	3.8e-05	0.00026	CcSEcCtD
Paliperidone—Rash—Irinotecan—lung cancer	3.8e-05	0.00026	CcSEcCtD
Paliperidone—Dermatitis—Irinotecan—lung cancer	3.8e-05	0.000259	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Docetaxel—lung cancer	3.8e-05	0.000259	CcSEcCtD
Paliperidone—Chills—Methotrexate—lung cancer	3.79e-05	0.000259	CcSEcCtD
Paliperidone—Headache—Irinotecan—lung cancer	3.78e-05	0.000258	CcSEcCtD
Paliperidone—Insomnia—Docetaxel—lung cancer	3.77e-05	0.000257	CcSEcCtD
Paliperidone—Diarrhoea—Cisplatin—lung cancer	3.74e-05	0.000256	CcSEcCtD
Paliperidone—Paraesthesia—Docetaxel—lung cancer	3.74e-05	0.000256	CcSEcCtD
Paliperidone—Alopecia—Methotrexate—lung cancer	3.73e-05	0.000255	CcSEcCtD
Paliperidone—Vomiting—Gemcitabine—lung cancer	3.73e-05	0.000255	CcSEcCtD
Paliperidone—Bradycardia—Doxorubicin—lung cancer	3.73e-05	0.000255	CcSEcCtD
Paliperidone—Dyspnoea—Docetaxel—lung cancer	3.71e-05	0.000254	CcSEcCtD
Paliperidone—Somnolence—Docetaxel—lung cancer	3.7e-05	0.000253	CcSEcCtD
Paliperidone—Mental disorder—Methotrexate—lung cancer	3.7e-05	0.000253	CcSEcCtD
Paliperidone—Rash—Gemcitabine—lung cancer	3.7e-05	0.000253	CcSEcCtD
Paliperidone—Dermatitis—Gemcitabine—lung cancer	3.7e-05	0.000253	CcSEcCtD
Paliperidone—Hypersensitivity—Etoposide—lung cancer	3.69e-05	0.000252	CcSEcCtD
Paliperidone—Erythema—Methotrexate—lung cancer	3.68e-05	0.000251	CcSEcCtD
Paliperidone—Malnutrition—Methotrexate—lung cancer	3.68e-05	0.000251	CcSEcCtD
Paliperidone—Headache—Gemcitabine—lung cancer	3.68e-05	0.000251	CcSEcCtD
Paliperidone—Rhinitis—Doxorubicin—lung cancer	3.67e-05	0.000251	CcSEcCtD
Paliperidone—Dyspepsia—Docetaxel—lung cancer	3.67e-05	0.000251	CcSEcCtD
Paliperidone—Hypoaesthesia—Doxorubicin—lung cancer	3.64e-05	0.000249	CcSEcCtD
Paliperidone—Decreased appetite—Docetaxel—lung cancer	3.62e-05	0.000247	CcSEcCtD
Paliperidone—Hypersensitivity—Paclitaxel—lung cancer	3.62e-05	0.000247	CcSEcCtD
Paliperidone—Urinary tract disorder—Doxorubicin—lung cancer	3.61e-05	0.000247	CcSEcCtD
Paliperidone—Oedema peripheral—Doxorubicin—lung cancer	3.61e-05	0.000246	CcSEcCtD
Paliperidone—Dysgeusia—Methotrexate—lung cancer	3.6e-05	0.000246	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Docetaxel—lung cancer	3.6e-05	0.000246	CcSEcCtD
Paliperidone—Asthenia—Etoposide—lung cancer	3.6e-05	0.000246	CcSEcCtD
Paliperidone—Connective tissue disorder—Doxorubicin—lung cancer	3.6e-05	0.000246	CcSEcCtD
Paliperidone—Fatigue—Docetaxel—lung cancer	3.59e-05	0.000245	CcSEcCtD
Paliperidone—Urethral disorder—Doxorubicin—lung cancer	3.59e-05	0.000245	CcSEcCtD
Paliperidone—Nausea—Irinotecan—lung cancer	3.58e-05	0.000245	CcSEcCtD
Paliperidone—Pain—Docetaxel—lung cancer	3.56e-05	0.000243	CcSEcCtD
Paliperidone—Constipation—Docetaxel—lung cancer	3.56e-05	0.000243	CcSEcCtD
Paliperidone—Back pain—Methotrexate—lung cancer	3.56e-05	0.000243	CcSEcCtD
Paliperidone—Pruritus—Etoposide—lung cancer	3.55e-05	0.000242	CcSEcCtD
Paliperidone—Asthenia—Paclitaxel—lung cancer	3.53e-05	0.000241	CcSEcCtD
Paliperidone—Nausea—Gemcitabine—lung cancer	3.49e-05	0.000238	CcSEcCtD
Paliperidone—Vomiting—Cisplatin—lung cancer	3.48e-05	0.000238	CcSEcCtD
Paliperidone—Pruritus—Paclitaxel—lung cancer	3.48e-05	0.000238	CcSEcCtD
Paliperidone—Vision blurred—Methotrexate—lung cancer	3.47e-05	0.000237	CcSEcCtD
Paliperidone—Rash—Cisplatin—lung cancer	3.45e-05	0.000236	CcSEcCtD
Paliperidone—Dermatitis—Cisplatin—lung cancer	3.45e-05	0.000235	CcSEcCtD
Paliperidone—Feeling abnormal—Docetaxel—lung cancer	3.43e-05	0.000235	CcSEcCtD
Paliperidone—Diarrhoea—Etoposide—lung cancer	3.43e-05	0.000234	CcSEcCtD
Paliperidone—Eye disorder—Doxorubicin—lung cancer	3.42e-05	0.000234	CcSEcCtD
Paliperidone—Ill-defined disorder—Methotrexate—lung cancer	3.41e-05	0.000233	CcSEcCtD
Paliperidone—Tinnitus—Doxorubicin—lung cancer	3.41e-05	0.000233	CcSEcCtD
Paliperidone—Gastrointestinal pain—Docetaxel—lung cancer	3.41e-05	0.000233	CcSEcCtD
Paliperidone—Anaemia—Methotrexate—lung cancer	3.4e-05	0.000232	CcSEcCtD
Paliperidone—Cardiac disorder—Doxorubicin—lung cancer	3.4e-05	0.000232	CcSEcCtD
Paliperidone—Flushing—Doxorubicin—lung cancer	3.4e-05	0.000232	CcSEcCtD
Paliperidone—Diarrhoea—Paclitaxel—lung cancer	3.36e-05	0.00023	CcSEcCtD
Paliperidone—Angiopathy—Doxorubicin—lung cancer	3.32e-05	0.000227	CcSEcCtD
Paliperidone—Malaise—Methotrexate—lung cancer	3.32e-05	0.000227	CcSEcCtD
Paliperidone—Dizziness—Etoposide—lung cancer	3.32e-05	0.000226	CcSEcCtD
Paliperidone—Immune system disorder—Doxorubicin—lung cancer	3.31e-05	0.000226	CcSEcCtD
Paliperidone—Vertigo—Methotrexate—lung cancer	3.31e-05	0.000226	CcSEcCtD
Paliperidone—Mediastinal disorder—Doxorubicin—lung cancer	3.3e-05	0.000225	CcSEcCtD
Paliperidone—Body temperature increased—Docetaxel—lung cancer	3.29e-05	0.000225	CcSEcCtD
Paliperidone—Abdominal pain—Docetaxel—lung cancer	3.29e-05	0.000225	CcSEcCtD
Paliperidone—Leukopenia—Methotrexate—lung cancer	3.29e-05	0.000225	CcSEcCtD
Paliperidone—Chills—Doxorubicin—lung cancer	3.28e-05	0.000224	CcSEcCtD
Paliperidone—Dizziness—Paclitaxel—lung cancer	3.25e-05	0.000222	CcSEcCtD
Paliperidone—Nausea—Cisplatin—lung cancer	3.25e-05	0.000222	CcSEcCtD
Paliperidone—Alopecia—Doxorubicin—lung cancer	3.23e-05	0.000221	CcSEcCtD
Paliperidone—Cough—Methotrexate—lung cancer	3.21e-05	0.000219	CcSEcCtD
Paliperidone—Mental disorder—Doxorubicin—lung cancer	3.21e-05	0.000219	CcSEcCtD
Paliperidone—Convulsion—Methotrexate—lung cancer	3.19e-05	0.000218	CcSEcCtD
Paliperidone—Vomiting—Etoposide—lung cancer	3.19e-05	0.000218	CcSEcCtD
Paliperidone—Malnutrition—Doxorubicin—lung cancer	3.19e-05	0.000218	CcSEcCtD
Paliperidone—Erythema—Doxorubicin—lung cancer	3.19e-05	0.000218	CcSEcCtD
Paliperidone—Rash—Etoposide—lung cancer	3.16e-05	0.000216	CcSEcCtD
Paliperidone—Dermatitis—Etoposide—lung cancer	3.16e-05	0.000216	CcSEcCtD
Paliperidone—Headache—Etoposide—lung cancer	3.14e-05	0.000215	CcSEcCtD
Paliperidone—Flatulence—Doxorubicin—lung cancer	3.14e-05	0.000214	CcSEcCtD
Paliperidone—Myalgia—Methotrexate—lung cancer	3.13e-05	0.000214	CcSEcCtD
Paliperidone—Chest pain—Methotrexate—lung cancer	3.13e-05	0.000214	CcSEcCtD
Paliperidone—Arthralgia—Methotrexate—lung cancer	3.13e-05	0.000214	CcSEcCtD
Paliperidone—Tension—Doxorubicin—lung cancer	3.13e-05	0.000214	CcSEcCtD
Paliperidone—Vomiting—Paclitaxel—lung cancer	3.13e-05	0.000213	CcSEcCtD
Paliperidone—Dysgeusia—Doxorubicin—lung cancer	3.12e-05	0.000213	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	3.11e-05	0.000213	CcSEcCtD
Paliperidone—Rash—Paclitaxel—lung cancer	3.1e-05	0.000212	CcSEcCtD
Paliperidone—Dermatitis—Paclitaxel—lung cancer	3.1e-05	0.000212	CcSEcCtD
Paliperidone—Discomfort—Methotrexate—lung cancer	3.09e-05	0.000211	CcSEcCtD
Paliperidone—Nervousness—Doxorubicin—lung cancer	3.09e-05	0.000211	CcSEcCtD
Paliperidone—Back pain—Doxorubicin—lung cancer	3.08e-05	0.000211	CcSEcCtD
Paliperidone—Headache—Paclitaxel—lung cancer	3.08e-05	0.00021	CcSEcCtD
Paliperidone—Hypersensitivity—Docetaxel—lung cancer	3.07e-05	0.00021	CcSEcCtD
Paliperidone—Muscle spasms—Doxorubicin—lung cancer	3.06e-05	0.000209	CcSEcCtD
Paliperidone—Confusional state—Methotrexate—lung cancer	3.03e-05	0.000207	CcSEcCtD
Paliperidone—Anaphylactic shock—Methotrexate—lung cancer	3e-05	0.000205	CcSEcCtD
Paliperidone—Vision blurred—Doxorubicin—lung cancer	3e-05	0.000205	CcSEcCtD
Paliperidone—Asthenia—Docetaxel—lung cancer	2.99e-05	0.000204	CcSEcCtD
Paliperidone—Infection—Methotrexate—lung cancer	2.98e-05	0.000204	CcSEcCtD
Paliperidone—Nausea—Etoposide—lung cancer	2.98e-05	0.000203	CcSEcCtD
Paliperidone—Ill-defined disorder—Doxorubicin—lung cancer	2.96e-05	0.000202	CcSEcCtD
Paliperidone—Pruritus—Docetaxel—lung cancer	2.95e-05	0.000201	CcSEcCtD
Paliperidone—Nervous system disorder—Methotrexate—lung cancer	2.94e-05	0.000201	CcSEcCtD
Paliperidone—Anaemia—Doxorubicin—lung cancer	2.94e-05	0.000201	CcSEcCtD
Paliperidone—Thrombocytopenia—Methotrexate—lung cancer	2.94e-05	0.000201	CcSEcCtD
Paliperidone—Agitation—Doxorubicin—lung cancer	2.93e-05	0.0002	CcSEcCtD
Paliperidone—Nausea—Paclitaxel—lung cancer	2.92e-05	0.000199	CcSEcCtD
Paliperidone—Skin disorder—Methotrexate—lung cancer	2.92e-05	0.000199	CcSEcCtD
Paliperidone—Malaise—Doxorubicin—lung cancer	2.87e-05	0.000196	CcSEcCtD
Paliperidone—Vertigo—Doxorubicin—lung cancer	2.86e-05	0.000196	CcSEcCtD
Paliperidone—Anorexia—Methotrexate—lung cancer	2.86e-05	0.000196	CcSEcCtD
Paliperidone—Syncope—Doxorubicin—lung cancer	2.86e-05	0.000195	CcSEcCtD
Paliperidone—Leukopenia—Doxorubicin—lung cancer	2.85e-05	0.000195	CcSEcCtD
Paliperidone—Diarrhoea—Docetaxel—lung cancer	2.85e-05	0.000195	CcSEcCtD
Paliperidone—Palpitations—Doxorubicin—lung cancer	2.82e-05	0.000192	CcSEcCtD
Paliperidone—Hypotension—Methotrexate—lung cancer	2.81e-05	0.000192	CcSEcCtD
Paliperidone—Loss of consciousness—Doxorubicin—lung cancer	2.8e-05	0.000191	CcSEcCtD
Paliperidone—Cough—Doxorubicin—lung cancer	2.78e-05	0.00019	CcSEcCtD
Paliperidone—Convulsion—Doxorubicin—lung cancer	2.76e-05	0.000189	CcSEcCtD
Paliperidone—Dizziness—Docetaxel—lung cancer	2.76e-05	0.000188	CcSEcCtD
Paliperidone—Hypertension—Doxorubicin—lung cancer	2.75e-05	0.000188	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Methotrexate—lung cancer	2.74e-05	0.000187	CcSEcCtD
Paliperidone—Insomnia—Methotrexate—lung cancer	2.72e-05	0.000186	CcSEcCtD
Paliperidone—Myalgia—Doxorubicin—lung cancer	2.71e-05	0.000185	CcSEcCtD
Paliperidone—Arthralgia—Doxorubicin—lung cancer	2.71e-05	0.000185	CcSEcCtD
Paliperidone—Chest pain—Doxorubicin—lung cancer	2.71e-05	0.000185	CcSEcCtD
Paliperidone—Anxiety—Doxorubicin—lung cancer	2.7e-05	0.000185	CcSEcCtD
Paliperidone—Paraesthesia—Methotrexate—lung cancer	2.7e-05	0.000184	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	2.69e-05	0.000184	CcSEcCtD
Paliperidone—Discomfort—Doxorubicin—lung cancer	2.68e-05	0.000183	CcSEcCtD
Paliperidone—Dyspnoea—Methotrexate—lung cancer	2.68e-05	0.000183	CcSEcCtD
Paliperidone—Somnolence—Methotrexate—lung cancer	2.67e-05	0.000182	CcSEcCtD
Paliperidone—Dry mouth—Doxorubicin—lung cancer	2.65e-05	0.000181	CcSEcCtD
Paliperidone—Vomiting—Docetaxel—lung cancer	2.65e-05	0.000181	CcSEcCtD
Paliperidone—Dyspepsia—Methotrexate—lung cancer	2.64e-05	0.000181	CcSEcCtD
Paliperidone—Rash—Docetaxel—lung cancer	2.63e-05	0.000179	CcSEcCtD
Paliperidone—Dermatitis—Docetaxel—lung cancer	2.62e-05	0.000179	CcSEcCtD
Paliperidone—Confusional state—Doxorubicin—lung cancer	2.62e-05	0.000179	CcSEcCtD
Paliperidone—Decreased appetite—Methotrexate—lung cancer	2.61e-05	0.000178	CcSEcCtD
Paliperidone—Headache—Docetaxel—lung cancer	2.61e-05	0.000178	CcSEcCtD
Paliperidone—Anaphylactic shock—Doxorubicin—lung cancer	2.6e-05	0.000178	CcSEcCtD
Paliperidone—Oedema—Doxorubicin—lung cancer	2.6e-05	0.000178	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Methotrexate—lung cancer	2.59e-05	0.000177	CcSEcCtD
Paliperidone—Fatigue—Methotrexate—lung cancer	2.59e-05	0.000177	CcSEcCtD
Paliperidone—Infection—Doxorubicin—lung cancer	2.58e-05	0.000176	CcSEcCtD
Paliperidone—Pain—Methotrexate—lung cancer	2.57e-05	0.000175	CcSEcCtD
Paliperidone—Shock—Doxorubicin—lung cancer	2.56e-05	0.000175	CcSEcCtD
Paliperidone—Nervous system disorder—Doxorubicin—lung cancer	2.55e-05	0.000174	CcSEcCtD
Paliperidone—Thrombocytopenia—Doxorubicin—lung cancer	2.55e-05	0.000174	CcSEcCtD
Paliperidone—Tachycardia—Doxorubicin—lung cancer	2.54e-05	0.000173	CcSEcCtD
Paliperidone—Skin disorder—Doxorubicin—lung cancer	2.53e-05	0.000173	CcSEcCtD
Paliperidone—Anorexia—Doxorubicin—lung cancer	2.48e-05	0.000169	CcSEcCtD
Paliperidone—Nausea—Docetaxel—lung cancer	2.47e-05	0.000169	CcSEcCtD
Paliperidone—Feeling abnormal—Methotrexate—lung cancer	2.47e-05	0.000169	CcSEcCtD
Paliperidone—Gastrointestinal pain—Methotrexate—lung cancer	2.46e-05	0.000168	CcSEcCtD
Paliperidone—Hypotension—Doxorubicin—lung cancer	2.43e-05	0.000166	CcSEcCtD
Paliperidone—Urticaria—Methotrexate—lung cancer	2.39e-05	0.000163	CcSEcCtD
Paliperidone—Abdominal pain—Methotrexate—lung cancer	2.37e-05	0.000162	CcSEcCtD
Paliperidone—Body temperature increased—Methotrexate—lung cancer	2.37e-05	0.000162	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Doxorubicin—lung cancer	2.37e-05	0.000162	CcSEcCtD
Paliperidone—Insomnia—Doxorubicin—lung cancer	2.35e-05	0.000161	CcSEcCtD
Paliperidone—Paraesthesia—Doxorubicin—lung cancer	2.33e-05	0.000159	CcSEcCtD
Paliperidone—Dyspnoea—Doxorubicin—lung cancer	2.32e-05	0.000158	CcSEcCtD
Paliperidone—Somnolence—Doxorubicin—lung cancer	2.31e-05	0.000158	CcSEcCtD
Paliperidone—Dyspepsia—Doxorubicin—lung cancer	2.29e-05	0.000156	CcSEcCtD
Paliperidone—Decreased appetite—Doxorubicin—lung cancer	2.26e-05	0.000154	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Doxorubicin—lung cancer	2.24e-05	0.000153	CcSEcCtD
Paliperidone—Fatigue—Doxorubicin—lung cancer	2.24e-05	0.000153	CcSEcCtD
Paliperidone—Constipation—Doxorubicin—lung cancer	2.22e-05	0.000152	CcSEcCtD
Paliperidone—Pain—Doxorubicin—lung cancer	2.22e-05	0.000152	CcSEcCtD
Paliperidone—Hypersensitivity—Methotrexate—lung cancer	2.21e-05	0.000151	CcSEcCtD
Paliperidone—Asthenia—Methotrexate—lung cancer	2.15e-05	0.000147	CcSEcCtD
Paliperidone—Feeling abnormal—Doxorubicin—lung cancer	2.14e-05	0.000146	CcSEcCtD
Paliperidone—Gastrointestinal pain—Doxorubicin—lung cancer	2.13e-05	0.000145	CcSEcCtD
Paliperidone—Pruritus—Methotrexate—lung cancer	2.12e-05	0.000145	CcSEcCtD
Paliperidone—Urticaria—Doxorubicin—lung cancer	2.07e-05	0.000141	CcSEcCtD
Paliperidone—Body temperature increased—Doxorubicin—lung cancer	2.06e-05	0.00014	CcSEcCtD
Paliperidone—Abdominal pain—Doxorubicin—lung cancer	2.06e-05	0.00014	CcSEcCtD
Paliperidone—Diarrhoea—Methotrexate—lung cancer	2.05e-05	0.00014	CcSEcCtD
Paliperidone—Dizziness—Methotrexate—lung cancer	1.99e-05	0.000136	CcSEcCtD
Paliperidone—Hypersensitivity—Doxorubicin—lung cancer	1.92e-05	0.000131	CcSEcCtD
Paliperidone—Vomiting—Methotrexate—lung cancer	1.91e-05	0.00013	CcSEcCtD
Paliperidone—Rash—Methotrexate—lung cancer	1.89e-05	0.000129	CcSEcCtD
Paliperidone—Dermatitis—Methotrexate—lung cancer	1.89e-05	0.000129	CcSEcCtD
Paliperidone—Headache—Methotrexate—lung cancer	1.88e-05	0.000129	CcSEcCtD
Paliperidone—Asthenia—Doxorubicin—lung cancer	1.87e-05	0.000127	CcSEcCtD
Paliperidone—Pruritus—Doxorubicin—lung cancer	1.84e-05	0.000126	CcSEcCtD
Paliperidone—Nausea—Methotrexate—lung cancer	1.78e-05	0.000122	CcSEcCtD
Paliperidone—Diarrhoea—Doxorubicin—lung cancer	1.78e-05	0.000122	CcSEcCtD
Paliperidone—Dizziness—Doxorubicin—lung cancer	1.72e-05	0.000117	CcSEcCtD
Paliperidone—Vomiting—Doxorubicin—lung cancer	1.65e-05	0.000113	CcSEcCtD
Paliperidone—Rash—Doxorubicin—lung cancer	1.64e-05	0.000112	CcSEcCtD
Paliperidone—Dermatitis—Doxorubicin—lung cancer	1.64e-05	0.000112	CcSEcCtD
Paliperidone—Headache—Doxorubicin—lung cancer	1.63e-05	0.000111	CcSEcCtD
Paliperidone—Nausea—Doxorubicin—lung cancer	1.54e-05	0.000106	CcSEcCtD
Paliperidone—HTR1A—Signaling Pathways—SRC—lung cancer	2.18e-06	3.59e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—STAT3—lung cancer	2.18e-06	3.59e-05	CbGpPWpGaD
Paliperidone—HRH1—GPCR downstream signaling—AKT1—lung cancer	2.18e-06	3.58e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—PIK3CA—lung cancer	2.18e-06	3.58e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PIK3CG—lung cancer	2.18e-06	3.58e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—NRAS—lung cancer	2.18e-06	3.58e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—EP300—lung cancer	2.17e-06	3.57e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—SRC—lung cancer	2.17e-06	3.57e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—ERBB2—lung cancer	2.17e-06	3.57e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CASP3—lung cancer	2.17e-06	3.56e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—IL2—lung cancer	2.16e-06	3.55e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CASP3—lung cancer	2.16e-06	3.55e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—IL2—lung cancer	2.16e-06	3.55e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—TP53—lung cancer	2.15e-06	3.54e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—IL6—lung cancer	2.15e-06	3.54e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—IL6—lung cancer	2.15e-06	3.53e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—PIK3CA—lung cancer	2.15e-06	3.53e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CCND1—lung cancer	2.14e-06	3.52e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MTOR—lung cancer	2.14e-06	3.52e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—PIK3CB—lung cancer	2.14e-06	3.52e-05	CbGpPWpGaD
Paliperidone—ADRA1A—GPCR downstream signaling—AKT1—lung cancer	2.14e-06	3.52e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—EP300—lung cancer	2.14e-06	3.52e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—JUN—lung cancer	2.14e-06	3.51e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—VEGFA—lung cancer	2.13e-06	3.5e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CASP3—lung cancer	2.12e-06	3.49e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—IL2—lung cancer	2.12e-06	3.48e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—VEGFA—lung cancer	2.12e-06	3.48e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—SRC—lung cancer	2.11e-06	3.47e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—EP300—lung cancer	2.11e-06	3.47e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—TP53—lung cancer	2.11e-06	3.47e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CCND1—lung cancer	2.11e-06	3.46e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—IL6—lung cancer	2.11e-06	3.46e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—STAT3—lung cancer	2.11e-06	3.46e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—JUN—lung cancer	2.1e-06	3.46e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CCND1—lung cancer	2.1e-06	3.46e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—KRAS—lung cancer	2.1e-06	3.46e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—NRAS—lung cancer	2.1e-06	3.45e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—JUN—lung cancer	2.1e-06	3.45e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—STAT3—lung cancer	2.09e-06	3.44e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—NRAS—lung cancer	2.09e-06	3.44e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—GSTP1—lung cancer	2.09e-06	3.43e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—MAPK3—lung cancer	2.08e-06	3.43e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—SRC—lung cancer	2.08e-06	3.42e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MMP9—lung cancer	2.08e-06	3.42e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—TP53—lung cancer	2.08e-06	3.41e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—KRAS—lung cancer	2.07e-06	3.41e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—POMC—lung cancer	2.07e-06	3.41e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CDKN1A—lung cancer	2.07e-06	3.41e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—PTEN—lung cancer	2.07e-06	3.4e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CCND1—lung cancer	2.06e-06	3.39e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—HRAS—lung cancer	2.06e-06	3.39e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—JUN—lung cancer	2.06e-06	3.39e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CXCL8—lung cancer	2.06e-06	3.38e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—VEGFA—lung cancer	2.06e-06	3.38e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MMP9—lung cancer	2.05e-06	3.36e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—HRAS—lung cancer	2.04e-06	3.36e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MMP9—lung cancer	2.04e-06	3.36e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CDKN1A—lung cancer	2.04e-06	3.35e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—STAT3—lung cancer	2.04e-06	3.35e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CDKN1A—lung cancer	2.03e-06	3.34e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—PTEN—lung cancer	2.03e-06	3.34e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—NRAS—lung cancer	2.03e-06	3.34e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CAT—lung cancer	2.03e-06	3.34e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—PTEN—lung cancer	2.03e-06	3.34e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—PTEN—lung cancer	2.03e-06	3.33e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—MYC—lung cancer	2.03e-06	3.33e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—VEGFA—lung cancer	2.03e-06	3.33e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—CREBBP—lung cancer	2.02e-06	3.32e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—HRAS—lung cancer	2.02e-06	3.32e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—AKT1—lung cancer	2.02e-06	3.32e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—MAPK3—lung cancer	2.01e-06	3.31e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—STAT3—lung cancer	2.01e-06	3.3e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MMP9—lung cancer	2e-06	3.29e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—MAPK3—lung cancer	2e-06	3.29e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—NRAS—lung cancer	2e-06	3.29e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CDKN1A—lung cancer	2e-06	3.28e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—PTEN—lung cancer	1.99e-06	3.27e-05	CbGpPWpGaD
Paliperidone—ADRA2A—GPCR downstream signaling—AKT1—lung cancer	1.99e-06	3.27e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—HRAS—lung cancer	1.99e-06	3.26e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—AKT1—lung cancer	1.98e-06	3.26e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—EGFR—lung cancer	1.98e-06	3.26e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—AKT1—lung cancer	1.98e-06	3.26e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—ABCB1—lung cancer	1.98e-06	3.25e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—IL6—lung cancer	1.97e-06	3.24e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—EP300—lung cancer	1.97e-06	3.24e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CASP3—lung cancer	1.97e-06	3.24e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—IL2—lung cancer	1.97e-06	3.23e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—IL6—lung cancer	1.96e-06	3.22e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—MYC—lung cancer	1.96e-06	3.22e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—MAPK3—lung cancer	1.95e-06	3.2e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—MYC—lung cancer	1.95e-06	3.2e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—AKT1—lung cancer	1.94e-06	3.19e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—TYMS—lung cancer	1.94e-06	3.19e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—EP300—lung cancer	1.94e-06	3.19e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—EP300—lung cancer	1.94e-06	3.18e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—EP300—lung cancer	1.93e-06	3.18e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—PIK3CA—lung cancer	1.93e-06	3.18e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—IL6—lung cancer	1.93e-06	3.17e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—PIK3CA—lung cancer	1.92e-06	3.16e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—GSTM1—lung cancer	1.92e-06	3.15e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CCND1—lung cancer	1.92e-06	3.15e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—SRC—lung cancer	1.92e-06	3.15e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—MAPK3—lung cancer	1.92e-06	3.15e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PIK3CD—lung cancer	1.91e-06	3.15e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—EGFR—lung cancer	1.91e-06	3.15e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—JUN—lung cancer	1.91e-06	3.15e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—PIK3CA—lung cancer	1.91e-06	3.13e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—EGFR—lung cancer	1.9e-06	3.13e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—IL6—lung cancer	1.9e-06	3.12e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—EP300—lung cancer	1.9e-06	3.12e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—MYC—lung cancer	1.89e-06	3.11e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—ALB—lung cancer	1.89e-06	3.11e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—SRC—lung cancer	1.89e-06	3.1e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—SRC—lung cancer	1.88e-06	3.09e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—KRAS—lung cancer	1.87e-06	3.08e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—TP53—lung cancer	1.87e-06	3.07e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—VEGFA—lung cancer	1.87e-06	3.07e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—MYC—lung cancer	1.86e-06	3.06e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MMP9—lung cancer	1.86e-06	3.06e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CDKN1A—lung cancer	1.85e-06	3.05e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—EGFR—lung cancer	1.85e-06	3.04e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—PTEN—lung cancer	1.85e-06	3.04e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—STAT3—lung cancer	1.85e-06	3.04e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—SRC—lung cancer	1.85e-06	3.04e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—NRAS—lung cancer	1.84e-06	3.03e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—TP53—lung cancer	1.84e-06	3.03e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—VEGFA—lung cancer	1.84e-06	3.02e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—VEGFA—lung cancer	1.83e-06	3.01e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—EGFR—lung cancer	1.82e-06	3e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—STAT3—lung cancer	1.82e-06	2.99e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—AKT1—lung cancer	1.82e-06	2.99e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CYP1A1—lung cancer	1.82e-06	2.99e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—STAT3—lung cancer	1.82e-06	2.98e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—NRAS—lung cancer	1.81e-06	2.98e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—NRAS—lung cancer	1.81e-06	2.98e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—KRAS—lung cancer	1.81e-06	2.97e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—AKT1—lung cancer	1.81e-06	2.97e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—ERCC2—lung cancer	1.8e-06	2.96e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—VEGFA—lung cancer	1.8e-06	2.96e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—KRAS—lung cancer	1.8e-06	2.96e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—HRAS—lung cancer	1.79e-06	2.94e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—AKT1—lung cancer	1.78e-06	2.93e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—STAT3—lung cancer	1.78e-06	2.93e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—NRAS—lung cancer	1.78e-06	2.92e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MAPK3—lung cancer	1.77e-06	2.9e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—EP300—lung cancer	1.76e-06	2.9e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—HRAS—lung cancer	1.76e-06	2.9e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—AKT1—lung cancer	1.75e-06	2.88e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—KRAS—lung cancer	1.75e-06	2.88e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MAPK3—lung cancer	1.74e-06	2.86e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MAPK3—lung cancer	1.73e-06	2.85e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—KRAS—lung cancer	1.72e-06	2.83e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—PIK3CA—lung cancer	1.72e-06	2.83e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MYC—lung cancer	1.72e-06	2.82e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—SRC—lung cancer	1.72e-06	2.82e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—IL6—lung cancer	1.71e-06	2.81e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MAPK3—lung cancer	1.7e-06	2.8e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MYC—lung cancer	1.69e-06	2.78e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—IL6—lung cancer	1.69e-06	2.77e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MYC—lung cancer	1.69e-06	2.77e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—EGFR—lung cancer	1.68e-06	2.76e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—VEGFA—lung cancer	1.67e-06	2.75e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PIK3CB—lung cancer	1.67e-06	2.74e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—TP53—lung cancer	1.66e-06	2.74e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—PIK3CA—lung cancer	1.66e-06	2.73e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MYC—lung cancer	1.66e-06	2.72e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—STAT3—lung cancer	1.66e-06	2.72e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PTGS2—lung cancer	1.65e-06	2.72e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—EGFR—lung cancer	1.65e-06	2.72e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—PIK3CA—lung cancer	1.65e-06	2.72e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—NRAS—lung cancer	1.65e-06	2.71e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—EGFR—lung cancer	1.65e-06	2.71e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—EGFR—lung cancer	1.62e-06	2.66e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—PIK3CA—lung cancer	1.61e-06	2.64e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—TP53—lung cancer	1.61e-06	2.64e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—TP53—lung cancer	1.6e-06	2.63e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—HRAS—lung cancer	1.59e-06	2.62e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—KRAS—lung cancer	1.59e-06	2.61e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—PIK3CA—lung cancer	1.58e-06	2.6e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MAPK3—lung cancer	1.58e-06	2.6e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—AKT1—lung cancer	1.58e-06	2.59e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—AKT1—lung cancer	1.57e-06	2.58e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—KRAS—lung cancer	1.56e-06	2.57e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—PIK3CA—lung cancer	1.56e-06	2.57e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—APOA1—lung cancer	1.56e-06	2.56e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—KRAS—lung cancer	1.56e-06	2.56e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—AKT1—lung cancer	1.56e-06	2.56e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—TP53—lung cancer	1.55e-06	2.56e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MYC—lung cancer	1.54e-06	2.53e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—HRAS—lung cancer	1.54e-06	2.53e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—TP53—lung cancer	1.53e-06	2.52e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—KRAS—lung cancer	1.53e-06	2.51e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—HRAS—lung cancer	1.53e-06	2.51e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—IL6—lung cancer	1.52e-06	2.51e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—EGFR—lung cancer	1.5e-06	2.47e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—HRAS—lung cancer	1.49e-06	2.44e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—IL6—lung cancer	1.47e-06	2.42e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—HRAS—lung cancer	1.46e-06	2.41e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—IL6—lung cancer	1.46e-06	2.41e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—PIK3CA—lung cancer	1.46e-06	2.4e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PTEN—lung cancer	1.44e-06	2.37e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—PIK3CA—lung cancer	1.43e-06	2.36e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—PIK3CA—lung cancer	1.43e-06	2.35e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—PIK3CA—lung cancer	1.43e-06	2.35e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PIK3CG—lung cancer	1.42e-06	2.34e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—IL6—lung cancer	1.42e-06	2.34e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—KRAS—lung cancer	1.42e-06	2.34e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—TP53—lung cancer	1.41e-06	2.32e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—AKT1—lung cancer	1.41e-06	2.31e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—PIK3CA—lung cancer	1.41e-06	2.31e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—IL6—lung cancer	1.4e-06	2.3e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—TP53—lung cancer	1.39e-06	2.28e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—TP53—lung cancer	1.39e-06	2.28e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—EP300—lung cancer	1.38e-06	2.26e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—TP53—lung cancer	1.36e-06	2.23e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—AKT1—lung cancer	1.36e-06	2.23e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—POMC—lung cancer	1.36e-06	2.23e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—AKT1—lung cancer	1.35e-06	2.22e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—HRAS—lung cancer	1.35e-06	2.22e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—HRAS—lung cancer	1.33e-06	2.18e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—HRAS—lung cancer	1.32e-06	2.18e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CREBBP—lung cancer	1.32e-06	2.17e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—AKT1—lung cancer	1.31e-06	2.16e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—PIK3CA—lung cancer	1.31e-06	2.15e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—HRAS—lung cancer	1.3e-06	2.14e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—AKT1—lung cancer	1.29e-06	2.12e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—IL6—lung cancer	1.29e-06	2.12e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—AKT1—lung cancer	1.28e-06	2.1e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—IL6—lung cancer	1.27e-06	2.09e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—IL6—lung cancer	1.27e-06	2.08e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—TP53—lung cancer	1.26e-06	2.08e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PIK3CD—lung cancer	1.25e-06	2.06e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—IL6—lung cancer	1.24e-06	2.05e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—ALB—lung cancer	1.24e-06	2.03e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—HRAS—lung cancer	1.21e-06	1.99e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—AKT1—lung cancer	1.19e-06	1.96e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—AKT1—lung cancer	1.17e-06	1.93e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—AKT1—lung cancer	1.17e-06	1.92e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—AKT1—lung cancer	1.17e-06	1.92e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—IL6—lung cancer	1.16e-06	1.9e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—AKT1—lung cancer	1.15e-06	1.89e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PIK3CB—lung cancer	1.09e-06	1.79e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PTGS2—lung cancer	1.08e-06	1.78e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—AKT1—lung cancer	1.07e-06	1.75e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PIK3CA—lung cancer	1.02e-06	1.67e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PTEN—lung cancer	9.43e-07	1.55e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—EP300—lung cancer	8.99e-07	1.48e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—AKT1—lung cancer	8.31e-07	1.37e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PIK3CA—lung cancer	6.65e-07	1.09e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—AKT1—lung cancer	5.43e-07	8.93e-06	CbGpPWpGaD
